Literature DB >> 3801083

Effect of very low molecular weight heparin-derived oligosaccharides on lipoprotein lipase release in rabbits.

Z M Merchant, E E Erbe, W P Eddy, D Patel, R J Linhardt.   

Abstract

Oligosaccharide fragments of heparin were prepared using flavobacterial heparinase. Following sizing, these oligosaccharide fractions were administered (i.v.) to rabbits and were examined for their ability to release lipoprotein lipase. The decasaccharides (dp = 10, Mr avg = 2,800) were the smallest oligosaccharides which resulted in substantial lipase release. The plasma lipase levels obtained with decasaccharides were comparable to low molecular weight heparin and one-third those obtained when heparin was administered at an equivalent dose. The peak plasma lipase concentration was observed 10 min following heparinization and fell off rapidly over the 60-min time course. The lipase release activity paralleled the in vivo pharmacokinetics of the heparin and decasaccharide sample as determined by monitoring their anti-Factor Xa activity. No activation of purified bovine milk lipoprotein lipase or plasma lipase was detectable at the concentrations studied, indicating that the increase in circulating lipolytic activity was due entirely to release. Lipoprotein lipase accounted for a major portion of the released activity with hepatic triglyceride lipase representing the remainder of the lipolytic activity. The sized decasaccharide sample was characterized with regards to its structure and anticoagulant activity. The decasaccharides exhibited reduced anticoagulant activity possibly making it a better drug candidate in the treatment of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3801083     DOI: 10.1016/0021-9150(86)90061-4

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  8 in total

1.  Heparan sulfate 2-O-sulfotransferase is required for triglyceride-rich lipoprotein clearance.

Authors:  Kristin I Stanford; Lianchun Wang; Jan Castagnola; Danyin Song; Joseph R Bishop; Jillian R Brown; Roger Lawrence; Xaiomei Bai; Hiroko Habuchi; Masakazu Tanaka; Wellington V Cardoso; Koji Kimata; Jeffrey D Esko
Journal:  J Biol Chem       Date:  2009-11-04       Impact factor: 5.157

2.  [Low molecular weight heparin: how does it modify lipid metabolism in chronic hemodialysis patients?].

Authors:  H Schneider; Y Schmitt
Journal:  Klin Wochenschr       Date:  1991-10-18

3.  Interaction of heparin with synthetic antithrombin III peptide analogues.

Authors:  J Bae; U R Desai; A Pervin; E E Caldwell; J M Weiler; R J Linhardt
Journal:  Biochem J       Date:  1994-07-01       Impact factor: 3.857

4.  Heparin-decasaccharides impair the catabolism of chylomicrons.

Authors:  O Chevreuil; M Hultin; P Ostergaard; T Olivecrona
Journal:  Biochem J       Date:  1996-12-01       Impact factor: 3.857

5.  The release of heparinase from the periplasmic space of Flavobacterium heparinum by three-step osmotic shock.

Authors:  J J Zimmermann; K Oddie; R Langer; C L Cooney
Journal:  Appl Biochem Biotechnol       Date:  1991-08       Impact factor: 2.926

6.  Structure of heparin fragments with high affinity for lipoprotein lipase and inhibition of lipoprotein lipase binding to alpha 2-macroglobulin-receptor/low-density-lipoprotein-receptor-related protein by heparin fragments.

Authors:  A Larnkjaer; A Nykjaer; G Olivecrona; H Thøgersen; P B Ostergaard
Journal:  Biochem J       Date:  1995-04-01       Impact factor: 3.857

7.  Fractionation of heparin-derived oligosaccharides by gradient polyacrylamide-gel electrophoresis.

Authors:  K G Rice; M K Rottink; R J Linhardt
Journal:  Biochem J       Date:  1987-06-15       Impact factor: 3.857

8.  Interaction of size-fractionated heparins with lipoprotein lipase and hepatic lipase in the rat.

Authors:  G Liu; M Hultin; P Ostergaard; T Olivecrona
Journal:  Biochem J       Date:  1992-08-01       Impact factor: 3.857

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.